Trauma sales surpassed $9 billion in 2024, accounting for 15% of the $62 billion global orthopedic market. In this video we look at the current state of the foot and ankle market, the growth of core trauma and how smaller players are leveraging niche subsegments. We cover strategic moves by Zimmer Biomet, Stryker, OrthoPediatrics and Orthofix.
Mike Evers is an analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage. You can reach him by email.
Trauma sales surpassed $9 billion in 2024, accounting for 15% of the $62 billion global orthopedic market. In this video we look at the current state of the foot and ankle market, the growth of core trauma and how smaller players are leveraging niche subsegments. We cover strategic moves by Zimmer...
Trauma sales surpassed $9 billion in 2024, accounting for 15% of the $62 billion global orthopedic market. In this video we look at the current state of the foot and ankle market, the growth of core trauma and how smaller players are leveraging niche subsegments. We cover strategic moves by Zimmer Biomet, Stryker, OrthoPediatrics and Orthofix.
Mike Evers is an analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage. You can reach him by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.